|  |
| --- |
|  |

**NIR EYAL, D. Phil. • *CURRICULUM VITAE* •** October 16, 2022

# EDUCATION AND POST-DOCTORAL TRAINING

2004-2006 Harold T. Shapiro Postdoctoral Fellowship in Bioethics, Princeton University Center for Human Values

2002-2004 Postdoctoral Fellow, National Institutes of Health, Department of Clinical Bioethics

1998-2003 D.Phil., Politics (political philosophy)**,** Oxford University

1994-1998 MA, Philosophy, Hebrew University

1991-1994 BA, Philosophy and History, Tel Aviv University

# **ACADEMIC** APPOINTMENTS

|  |  |
| --- | --- |
| 2019-Pres. | Henry Rutgers Professor of Bioethics, at the Depts. of Philosophy (SAS) and Health Behavior and Social Policy (SPH); Founding Director, Center for Population-Level Bioethics (RBHS), Rutgers University |
| 2019-Pres. | Departmental Guest, Center for Human Values, Princeton University |
| 2015-2019 | Associate Professor, Dept. of Global Health and Population, Harvard TH Chan School of Public Health. Affiliated with the Concentration in Global Health and Health Policy, FAS, Harvard University; Harvard University Program in Ethics and Health (affiliated also with the Center for Bioethics, Harvard Medical School; Petrie-Flom Center, Harvard Law School; Secondary Concentration in Global Health and Health Policy, FAS; Center for Communicable Disease Dynamics, Harvard TH Chan School of Public Health) |
| 2018 | Visiting Professor, Department of Political Science, Hebrew University of Jerusalem |
| 2014-2015 | Associate Professor, Center for Bioethics, Harvard Medical School; Dept. of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University Program in Ethics and Health |
| 2012-2013 | Associate Professor, Division of Medical Ethics, Dept. of Global Health and Social Medicine, Harvard Medical School; Harvard University Program in Ethics and Health |
| 2008-2012 | Assistant Professor, Division of Medical Ethics, Dept. of Global Health and Social Medicine, Harvard Medical School; Harvard University Program in Ethics and Health |
| 2009-2010 | Faculty Fellow, EJ Safra Foundation Center for Ethics, Kennedy School of Government, Harvard University |
| 2006-2008 | Instructor, Division of Medical Ethics, Dept. of Global Health and Social Medicine, Harvard Medical School; Harvard University Program in Ethics and Health |

**PUBLICATIONS** \* Corresponding author

|  |
| --- |
| 1. Kahn R, **Eyal N**, Sow S, Lipsitch M. Mass drug administration of azithromycin: an analysis. *Clinical Microbiology and Infection*. forthcoming. 2. Steuwer B, **Eyal N**, Magalhaes M. Paired publication: a way to lower one barrier between philosophical insight and bioethics. *Amer J of Bioeth*. forthcoming. 3. Magalhaes M, Kuritzkes DR, **Eyal N**. The ethical case for placebo control in HIV-cure-related studies with ART interruption. *J of Viral Erad*. 2022;8(3). Epub Aug 28. doi: 10.1016/j.jve.2022.100084; PMCID: PMC9464947. 4. Steuwer B, **Eyal N**, Magalhaes M. Paired publication: a way to lower one barrier between philosophical insight and bioethics. *Amer J of Bioethics.* Forthcoming. 5. Bain LE, Berner-Rodoreda A, McMahon S, Sarker M, Tanser F, Bärnighausen, T, Wikler D, **Eyal N.** (2022)One lesson of Covid-19: Conduct more health policy trials. *PNAS,* 119 (24), 1-4*.* [10.1073/pnas.211988711](https://doi.org/10.1073/pnas.2119887119). 6. **Eyal N.** Gheaus A, Gosseries A, Magalhaes M, Ngosso T, Steuwer B, Tangcharoensathien V, Trifan I, Williams, A (2022). COVID vaccine prioritization in low-and middle-income countries may justifiably depart from high-income countries’ age priorities. *CID*, ciac398, [10.1093/cid/ciac398](https://doi.org/10.1093/cid/ciac398). 7. **Eyal N.** (2022)**.** Research ethics and public trust in vaccines: the case of COVID-19 challenge trials*. J Med Ethics,* 0; 1-7. 8. Rohrig A, **Eyal, N.** (2022). A new day for human challenge trials? *Trends in Molecul Med.* 9. Gerhard T, Strom B, **Eyal N**. (2022). **Pandemic vaccine testing: Combining conventional and challenge studies.** Pharmacoepidemiology and Drug Safety, May 21. [10.1002/pds.5429](http://dx.doi.org/10.1002/pds.5429) 10. Campbell JI\*, Musiimenta A, Natukunda S, **Eyal N**, Haberer JE (2022). “The research assistants kept coming to follow me up; I counted myself as a lucky person”: Social support arising from a longitudinal HIV cohort study in Uganda. *PLoS One*. Jan 25;17(1):e0262989. 10.1371/journal.pone.0262989.eCollection 2022. PMID: **35077497.** PMCID: [PMC8789171](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8789171/) 11. Berner-Rodoreda A\*, McMahon S, **Eyal N**, Hossain P, Rabbani A, Barua M, Sarker M, Metta E, Mmbaga E, Leshabari M, Wikler D, Bärnighausen T. Consent Requirements for Testing Health Policies: An Intercontinental Comparison of Expert Opinions. *J Emp Res Hum Res Ethics*. 2022. Epub February 10. [10.1177/15562646221076764](https://journals.sagepub.com/doi/10.1177/15562646221076764). 12. Rohrig,\* A, **Eyal, N**. (2021). The Ethics of Human Challenge Trials Using Emerging SARS-CoV-2 Virus Variants, *J Infect* *Dis*, jiab488. [10.1093/infdis/jiab488](https://doi.org/10.1093/infdis/jiab488). 13. Berner-Rodoreda, A,\* Bärnighausen, T, **Eyal, N**, et al. (2021). “Thought provoking”, “interactive”, and “more like a peer talk”: testing the deliberative interview style in Germany. *SSM - Qualitative Research in H*ealth 2021;1 Epub 21 September. [10.1016/j.ssmqr.2021.100007](https://doi.org/10.1016/j.ssmqr.2021.100007) 14. Steuwer, B, Jamrozik, E, **Eyal, N**\*, (2021). Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies, *IJID;* Vol. 105; 307-311. [10.1016/j.ijid.2021.02.038](https://doi.org/10.1016/j.ijid.2021.02.038). 15. **Eyal, N**, Herlitz, A.\* (2021). Input and output in distributive theory. *Noûs*. 1-23. [10.1111/nous.12392](https://doi.org/10.1111/nous.12392). 16. **Eyal, N**,\* Lipsitch, M. (2021). Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure. *Clin Microb and Infect*, 27(3), 372–377. [10.1016/j.cmi.2020.12.032](https://doi.org/10.1016/j.cmi.2020.12.032). 17. **Eyal N**,\* Gerhard T, Strom BL. (2021). Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests. *Vaccine*. Jun 11;39(26):3455-3458. [10.1016/j.vaccine.2021.04.056](https://doi.org/10.1016/j.vaccine.2021.04.056). Epub 2021 Apr 30. PMID: 34023137; PMCID: PMC8084609. 18. **Eyal N**,\* Gerhard T. Do coronavirus vaccine challenge trials have a distinctive generalisability problem? *J Med Ethics*. 2021 Jun 7. [10.1136/medethics-2020-107109](https://doi.org/10.1136/medethics-2020-107109). Epub ahead of print. PMID: 34099541. 19. Lee K, **Eyal N**.\* (2021) COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement. *J Med Ethics*; 47:539-542. PMID: 33980657, PMCID: PMC8117466. [10.1136/medethics-2021-107229](https://doi.org/10.1136/medethics-2021-107229). 20. **Eyal N**, Lipsitch, M (2021). How to Test Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Ethically Even After One Is Available, *Clin Infect Dis*, 73(12), 2332-2334, ciab182. [10.1093/cid/ciab182](https://doi.org/10.1093/cid/ciab182). 21. **Eyal, N**, Herlitz A. (2021). Symposium: ethics of economic ordeals. *Econ and Phil*; 37(1), 1-7. [10.1017/S0266267120000292](https://doi.org/10.1017/S0266267120000292). 22. Broockman D, Kalla J, Guerrero A, Budolfson M, **Eyal N**, Jewell NP, Magalhaes M, and Sekhon JS. 2021. Broad Cross-National Public Support for Accelerated COVID-19 Vaccine Trial Designs. *Vaccine*, 39 (2): 309-316. [10.1016/j.vaccine.2020.11.072](https://doi.org/10.1016/j.vaccine.2020.11.072). 23. Rosa Diaz P, Darz A, **Eyal N**. COVID-19 Challenge Trials Would Save Lives And Avert Years In Poverty By Significant Margins, " *Health Affairs Blog*, December 11, 2020. [10.1377/hblog20201208.92114](https://doi.org/10.1377/hblog20201208.92114). 24. **Eyal N,** Holtzman L. (2020). Symposium on risks to by bystanders in clinical research: an introduction. *Bioeth,* 2020; 34:879–882. [10.1111/bioe.12830](https://doi.org/10.1111/bioe.12830). 25. **Eyal N** 2020. Is there an ethical upper limit on risks to study participants? *Pub Health Eth*, 1-14. [10.1093/phe/phaa028](https://doi.org/10.1093/phe/phaa028). 26. **Eyal N** 2020**.** Study bystanders and ethical treatment of study participants—A proof of concept. *Bioeth.* 00: 1-7. [10.1111/bioe.12825](https://doi.org/10.1111/bioe.12825). 27. **Eyal N** 2020. Rescuing vapers vs. rescuing smokers: the ethics. *Nicot & Tobacco Res*. [10.1093/ntr/ntaa157](https://doi.org/10.1093/ntr/ntaa157). 28. **Eyal N**, Lipsitch M. 2020. Opinion: It’s ethical to test promising coronavirus vaccines against less-promising ones. *PNAS* . [10.1073/pnas.2014154117](https://doi.org/10.1073/pnas.2014154117). 29. Steel R\*, Buchak L, **Eyal N** 2020. Why Continuing Uncertainties Are No Reason to Postpone Challenge Trials for Coronavirus Vaccines. *J Med Ethics.* [10.1136/medethics-2020-106501](https://jme.bmj.com/content/early/2020/10/08/medethics-2020-106501). 30. **Eyal N**,\* Halkitis PN 2020. AIDS activism and Coronavirus vaccine challenge trials. *AIDS and Behav* 24(12) 3302-3305;E-pub 26 June. [10.1007/s10461-020-02953-8](file:///\\172.19.21.162\Users\nireyal\Documents\CV\3pp%20CV\10.1007\s10461-020-02953-8). 31. **Eyal N** 2020. Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events, *E&HR*, 42:1-11. [10.1002/eahr.500056](doi:10.1002/eahr.500056). 32. **Eyal N\***, Lipsitch M, Smith P. 2020. Human challenge studies to accelerate coronavirus vaccine licensure, *J Infect Dis*. E-pub 31 March. [10.1093/infdis/jiaa152](doi:%20%2010.1056/NEJMc2009666,); PMID: 32232474. 33. **Eyal N**, SA Hurst, CJL Murray, SA Schroeder and D Wikler (2020). Introduction: Philosophy and the Global Burden of Disease Study. *Measuring the Global Burden of Disease*. N Eyal, SA Hurst, CJL Murray, SA Schroeder and D Wikler. New York: Oxford UP. 34. **Eyal, N,\*** M Sjöstrand (2020). On Knowingly Setting Unrealistic Goals in Public Health. *Amer J of Pub Health* 110: 480-484. [10.2105/AJPH.2019.305428](https://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2019.305428). 35. **Eyal N**.2020. Measuring Health-State Utility via Cured Patients. *Disability, Health, Law, and Bioethics*. Ed. by I G Cohen, C Shachar, A Silvers and M A Stein. New York: Cambridge UP; 266–279. 36. Berner-Rodoreda A,\* et al, including **Eyal N** 2018. From doxastic to epistemic – a typology and critique of qualitative interview styles. *Qualitative Inquir;* 26(3-4), 291-305*.* [10.1177/1077800418810724](https://doi.org/10.1177/1077800418810724); PMID: 32038093 PMCID: PMC6985996 37. Kratka, A, et al. including **Eyal N**, 2019. HIV Cure Research: Risks Patients Expressed Willingness to Accept. *E&HR* 41, no. 6 23-34. [10.1002/eahr.500035](https://doi.org/10.1002/eahr.500035); PMID: 31743627 38. **Eyal N** & Magalhaes M. 2019. Is it ethical to isolate study participants to prevent HIV transmission during trials with an analytical treatment interruption? *J Infect Dis* 220(Supplement\_1): S19–S21. [10.1093/infdis/jiz164](https://doi.org/10.1093/infdis/jiz164); PMID: 31264688 PMCID: PMC6603965 39. **Eyal N**, et al. 2019. Regulating impact on bystanders in clinical trials: An unsettled frontier. *Clin Trials* 16(5): 450–454. [10.1177/1740774519862783](https://doi.org/10.1177/1740774519862783); PMID: 31368813 PMCID: PMC6742522 40. **Eyal N** & Deeks SG 2019. Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium. *J Infect Dis* 220(Supplement\_1): S1–S4. [10.1093/infdis/jiz173](https://doi.org/10.1093/infdis/jiz173); PMID: 31264687 PMCID: PMC6603969 41. **Eyal N** 2019. How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach. *J Infect Dis* 220(Supplement\_1): S7–S11. [10.1093/infdis/jiz163](https://doi.org/10.1093/infdis/jiz163); PMID: 31264692 PMCID: PMC6603962 42. **Eyal N** 2019. Removing One Barrier to Protecting Sex Partners in HIV Remission Studies With a Treatment Interruption. J *Infect Dis* 220(Supplement\_1): S22–S23. [10.1093/infdis/jiz162](https://doi.org/10.1093/infdis/jiz162); PMID: 31264690 PMCID: PMC6603972 43. **Eyal N** 2019. Risk to bystanders in clinical trials: A symposium. *Clin Trials* **16**(5): 447–49. [10.1177/1740774519862758](https://doi.org/10.1177/1740774519862758); PMID: 31368795 PMCID: PMC6742523 44. **Eyal N**, & Wikler D 2019. Ethical complexities of responding to bystander risk in HIV prevention trials. *Clinical Trials*, *16*(5),458–460. [10.1177/1740774519862765](https://doi.org/10.1177/1740774519862765) 45. Murray BR, Kratka A, Scherr KA, **Eyal N**, Blumenthal-Barby J, Freedburg K, Kuritzkes DR, Hammitt JK, Edifor R, Katz MN, Pollak KI, Zikmund-Fisher BJ, Halpern SD, Barks MC, Ubel PA, 2019. What Risk of Death Would People Take to be Cured of HIV, and Why? A Survey of People Living With HIV. *J Virus Education*, 5(2):109–115 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543487. 46. Zhang Y\*, Bärnighausen T, **Eyal N** 2019**.** When Global ART Budgets Cannot Cover All Patients, Who Should Be Eligible? *JAIDS*. E-Pub: 25 February. [10.1097/QAI.0000000000002017](https://doi.org/10.1097/QAI.0000000000002017). PMID: 30839381 PMCID: PMC6522313 47. Ng JWL\*, Sjöstrand M, **Eyal N** 2019**.** Adding Lithium to Drinking Water for Suicide Prevention—the Ethics. *Pub Health Eth*. E-Pub: 12 February. [10.1093/phe/phz002](https://doi.org/10.1093/phe/phz002). 48. Berner-Rodoreda A\*, et al, including **Eyal N** 2018**.** From doxastic to epistemic–a typology and critique of qualitative interview styles. *Qualitat Inquiry*. E-Pub: 28 November. [10.1177%2F1077800418810724](https://doi.org/10.1177%2F1077800418810724). 49. International Panel on Social Progress (IPSP), incl. **Eyal N** *Rethinking Society for the 21st Century (IPSP 2018 report).* New York: Cambridge UP 2018. In three volumes. I contributed to the chapter on health. 50. Campbell JI\*, Haberer JE, Musiimenta A, **Eyal N** 2018**.** Dependence on digital medicine in resource-limited settings. *Am J Bioeth*; 18(9): 54–56. E-Pub 20 September. [10.1080/15265161.2018.1498949](https://doi.org/10.1080/15265161.2018.1498949); PMID: 30265607 PMCID: PMC6203887. 51. **Eyal N\***, Lipsitch M, Bärnighausen T, Wikler D 2018. Risk to study nonparticipants: a procedural approach. *PNAS* 115(32):8051–53. [10.1073/pnas.1810920115](https://doi.org/10.1073/pnas.1810920115); PMID: 30087210 PMCID: PMC6094093. 52. Swanson KC\* et al, incl. **Eyal N** 2018**.** Contact tracing performance during the Ebola epidemic in Liberia, 2014–2015. *PLoS Negl Trop Dis*; 12(9):e0006762. [10.1371/journal.pntd.0006762](https://doi.org/10.1371/journal.pntd.0006762); PMID: 30208032 PMCID: PMC6152989. 53. Brown R\*, Deeks S, **Eyal N** 2018**,** Maximizing the global health impact of future HIV cure-related interventions through advance planning. *J Virus Erad*; 4(3):182–185. <https://www.ncbi.nlm.nih.gov/pubmed/30050682>; PMCID: 6038126. 54. Kahn R\*, Rid A, **Eyal N,** et al. 2018. Choices in vaccine trial design in epidemics of emerging infections. *PLoS Medicine*; 15(8). [10.1371/journal.pmed.1002632](https://doi.org/10.1371/journal.pmed.1002632); PMID: 30086139 PMCID: PMC6080746. 55. **Eyal N\***, Holtzman LG, Deeks S 2018. Ethical issues in HIV remission trials. *Curr Opin HIV AIDS*; 13(5):422–427. [10.1097/COH.0000000000000489](https://doi.org/10.1097/COH.0000000000000489). 56. Campbell J\***, Eyal N,** Mussiimenta A et al. 2018. Ugandan study participants experience electronic monitoring of antiretroviral therapy adherence as welcomed pressure to adhere. *AIDS Behav;* 1–10. [10.1007/s10461-018-2200-8](https://doi.org/10.1007/s10461-018-2200-8); PMID: 29926301 PMCID: PMC6309333. 57. **Eyal N\***, Romain P, Robertson C. Can rationing through inconvenience be ethical? *Hastings Ctr Rpt*;48(1):10–22. [10.1002/hast.806](https://doi.org/10.1002/hast.806); PMID: 29457241. 58. **Eyal N\***, Holtzman L 2018. Invited commentary on Dubé et al. (Perceptions of equipoise, risk/benefit ratios, and “otherwise healthy volunteers” in the context of early-phase HIV cure research in the United States–a qualitative inquiry): Are HIV-infected candidates for participation in risky cure-related studies otherwise healthy? *J Empir Res Hum Res Ethics*, 13(1):18-22. [10.1177/1556264617740244](https://doi.org/10.1177/1556264617740244); PMID: 29179624 PMCID: PMC6103447. 59. **Eyal N\*** 2018**.** What can the lived experience of participating in risky HIV cure-related studies establish? *J Med Ethics*; 44(4):277–278. [10.1136/medethics-2017-104593](https://doi.org/10.1136/medethics-2017-104593); PMID: 29321219 PMCID: PMC6093613. 60. Wu F, Zhang A, Babbitt A, Ma Q, **Eyal N\***, Pan X, Cai W, Hu F, Cheng Y, Tucker JD 2017. Overcoming HIV stigma? A qualitative analysis of HIV cure research and stigma among men who have sex with men living with HIV. *Arch Sex Behav*; 47(7):2061–2069. [10.1007/s10508-017-1062-x](https://doi.org/10.1007/s10508-017-1062-x); PMID: 29149399 PMCID: PMC5957764. 61. Lipsitch M\*, **Eyal N** 2017. Improving vaccine trials in infectious disease emergencies. *Science*; 357(6347):153–6. [10.1126/science.aam8334](https://doi.org/10.1126/science.aam8334); PMID: 28706038 PMCID: PMC5568786. 62. Dickert N\*, **Eyal N,** et al. 2017. Re-framing consent for clinical research: A function-based approach. *Amer J of Bioethics*; 17(12):3-11, with an editorial by T. Beauchamp. [10.1080/15265161.2017.1388448](https://doi.org/10.1080/15265161.2017.1388448); PMID: 29148951 63. Richardson HS, **Eyal N**, Campbell J et al. 2017. When ancillary care would compromise study aims. *N Engl J Med*; 377(13): 1213–1215. [10.1056%2FNEJMp1702651](https://dx.doi.org/10.1056%2FNEJMp1702651). 64. Voorhoeve AE, et al, including **Eyal N** 2017. Making fair choices on the path to universal health coverage: Applying principles to difficult cases. *Health Systems & Reform*; 301–312. 10.1080/23288604.2017.1324938; PMID: 30359178 65. **Eyal N** 2017**.** Afterword: Returning to philosophical foundations in research ethics. *J Med Ethics*; 43(2):132–133. [10.1136/medethics-2016-103429](https://doi.org/10.1136/medethics-2016-103429); PMID: 27354247 PMCID: PMC5191995. 66. **Eyal N** 2017. The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction. *J Med Ethics*; 43:65-66. [10.1136/medethics-2016-103427](https://doi.org/10.1136/medethics-2016-103427); PMID: 27215763 PMCID: PMC5121082. 67. **Eyal N** 2017. How to keep high-risk studies ethical: classifying candidate solutions. *J Med Ethics*; 43(2):74–77. [10.1136/medethics-2016-103428](https://doi.org/10.1136/medethics-2016-103428); PMID: 27288098 PMCID: PMC5148732. 68. **Eyal N\*,** Lipsitch M 2017. Vaccine testing for emerging infections: the case for individual randomisation. *J Med Ethics*; 43(9):625–631. [10.1136/medethics-2015-103220](https://doi.org/10.1136/medethics-2015-103220); PMID: 28396558 PMCID: PMC5577361. 69. **Eyal N**\*. Tieffenbach E 2017. Incommensurability and trade. *The Monist*; 99(4):387–405. [10.1093/monist/onw012](https://doi.org/10.1093/monist/onw012) 70. Voorhoeve AE\* et al, incl. **Eyal N** 2016. Three case studies in making fair choices on the path to universal health coverage. *Health Hum Rights;* 18(2):11–22. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395011/>. 71. **Eyal N**\*, Cancedda C, Hurst SA., Kyamanywa P 2017. Coordinating between medical professions’ tasks to optimize sub-Saharan health systems: a response to recent commentaries. *Int J Health Policy Manag*; 6(2):123–125. [10.15171/ijhpm.2016.142](https://doi.org/10.15171/ijhpm.2016.142); PMID: 28812790 PMCID: PMC5287930. 72. Deeks SG\* et al, incl. **Eyal N** 2016**.** International AIDS Society global scientific strategy: towards an HIV cure. *Nat Med*; 22(8):839–850. [10.1038/nm.4108](https://doi.org/10.1038/nm.4108); PMID: 27400264 PMCID: PMC5322797. 73. Healy J\*, Hope R, Bhabha J, **Eyal N** 2016**.** Paying for antiretroviral adherence: is it unethical when the patient is an adolescent? *J Med Ethics*; 43(3):135–136. [10.1136/medethics-2015-103359](https://doi.org/10.1136/medethics-2015-103359); PMID: 27645199. 74. Emhoff IA, Fugate E, **Eyal N**\* 2016. Is there a moral right to nonmedical vaccine exemption? *Am J Law Med*; 42: 598–620. [10.1177/0098858816658281](https://doi.org/10.1177/0098858816658281); PMID: 29086637. |
| 1. Zimmerman M,\* Shah S, Shakya R, Chansi BS, Shah K, Munday D, **Eyal N** & Hayes B 2016. Improving performance in Nepal’s rural hospitals through a ‘bundled’ program of human resource support. *WHO Bulletin* 94 [10.2471/BLT.15.153619](http://dx.doi.org/10.2471/BLT.15.153619); PMID: 26769998 PMCID: PMC4709798. 2. **Eyal N**,\* Cancedda C, Kyamanywa P, Hurst SA. 2016. Non-physician clinicians in sub-Saharan Africa and the evolving role of physicians. *Int J Health Policy Manag 5*: 1–5. With responses by Binagwaho et al, Cubaka et al, Dovlo et al, Dussault & Cobb, Monekosso, Olapade-Olaopa et al, and Sidat. [10.15171/ijhpm.2015.215](https://doi.org/10.15171/ijhpm.2015.215); PMID: 26927585PMCID: PMC4770920. 3. Campbell JI, **Eyal N**\*, Musiimenta A, Haberer J 2016. Ethical questions in medical electronic adherence monitoring. *J Gen Int Med*; 31(3):338–342. [10.1007/s11606-015-3502-4](https://doi.org/10.1007/s11606-015-3502-4); PMID: 26358284 PMCID: PMC4762813. 4. Bärnighausen T\*, **Eyal N**, Wikler D 2015. HIV treatment-as-prevention research: authors’reply. *PLoS Med*; 12(3): [10.1371/journal.pmed.1001799](https://doi.org/10.1371/journal.pmed.1001799); PMID: 25756214 PMCID: PMC4355408. 5. **Eyal N** 2015**.** Inequality in political philosophy and epidemiology: a remarriage. *J Applied Philosophy*; 35(1). 10.1111/japp.12150. 6. Murthi S\*, **Eyal N,** Norheim OF, Ruan DT, Ntakiyiruta G, Riviello R 2015. Standard of care vs. second-best: Ethical dilemmas in surgery for high risk papillary thyroid cancer in low and middle-income countries. *J Canc Pol*; 6:8–10. [10.1016/j.jcpo.2015.08.006](https://doi.org/10.1016/j.jcpo.2015.08.006). |
| 1. **Eyal N** 2015. Informed consent to participation in interventional studies: second-order in a different sense. *J Law Biosci*; 2(1):123–128. [10.1093/jlb/lsv001](https://doi.org/10.1093/jlb/lsv001); PMID: 27774189 PMCID: PMC5033560. |
| 1. Lipsitch M,\* **Eyal N,** Halloran E, Hernán MA, Longini IM, Perencevich,EN, Grais RF\* 2015. Vaccine testing: Ebola and beyond. *Science Magazine*; 348(6230):46–48. [10.1126/science.aaa3178](https://doi.org/10.1126/science.aaa3178); PMID: 25838371 PMCID: PMC4408019. |
| 1. **Eyal N** 2015.Nudge, embarrassment, and restriction—replies to Voigt, Tieffenbach, and Saghai. *Int J Health Policy Manag*; 4(1):53–54. [10.15171/ijhpm.2015.01](https://doi.org/10.15171/ijhpm.2015.01); PMID: 25584355 PMCID: PMC4289039. |
| 1. Ottersen T, Norheim OF\* 2014. On behalf of the World Health Organization Consultative Group on Equity and Universal Health Coverage, including **Eyal N** Making fair choices on the path to universal health coverage. *Bulletin of the World Health Organization*; 92:389. [10.2471/BLT.14.139139](https://doi.org/10.2471/BLT.14.139139); PMID: 24940009 PMCID: PMC4047814. 2. **Eyal N** 2014.Pediatric heart surgery in Ghana: Three ethical questions. *J Clin Ethics*; 25(4):317-23. PMID: 25517570. |
| 1. **Eyal N** 2014 Non-consequentialist utilitarianism. *Revue Éthique et Économique*; 11(2):34–53 <http://hdl.handle.net/1866/10932>. |
| 1. **Eyal N** 2014**.** Two kinds of to-kind benefits and other reasons why shared vulnerability can keep clinical studies ethical. *Amer J Bioethics*; 14(12):22–24. [10.1080/15265161.2014.964880](https://doi.org/10.1080/15265161.2014.964880); PMID: 25369411. |
| 1. **Eyal N** 2014.Nudging by shaming, shaming by nudging. *Int J Health Policy Manag*; 3:1–4. [10.15171/ijhpm.2014.68](https://doi.org/10.15171/ijhpm.2014.68) |
| 1. Bärnighausen T**\*,** **Eyal N**, Wikler D 2014. HIV Treatment-as-prevention at a crossroads. *PLoS Medicine*; 11: e1001654. [10.1371/journal.pmed.1001654](https://doi.org/10.1371/journal.pmed.1001654); PMID: 24892694 PMCID: PMC4043489. |
| 1. **Eyal N,** Kuritzkes D**\*** 2014. Challenges in clinical trial design for HIV cure research. *Lancet*; 382:1464-1465. [10.1016/S0140-6736(13)62040-1](https://doi.org/10.1016/S0140-6736(13)62040-1); PMID: 24182529. |
| 1. **Eyal N** 2013. Paternalism, French fries and the weak-willed Witness. *J Med Ethics*; 40:353–354. [10.1136/medethics-2013-101555](https://doi.org/10.1136/medethics-2013-101555); PMID: 24335857. |
| 1. Wikler D, **Eyal N\*** 2013. Nudges and noodges: the ethics of health promotion—New York style. *Pub Health Eth.*; 3(6): 233–234. [10.1093/phe/pht033](https://doi.org/10.1093/phe/pht033). |
| 1. **Eyal N** 2013. Sticking with carrots and sticks (sticking points aside): A response to Ventakapuram, Goldberg, and Forrow. *International J of Health Policy & Management*; 1:317–318. [10.15171/ijhpm.2013.64](https://doi.org/10.15171/ijhpm.2013.64); PMID: 24596892 PMCID: PMC3937905. |
| 1. **Eyal N** 2013.Denial of treatment to obese patients—the wrong policy on personal responsibility for health. *Int J Health Policy Manag*; 1(2):Article 5; 107–110. [10.15171/ijhpm.2013.18](https://doi.org/10.15171/ijhpm.2013.18); PMID: 24596846 PMCID: PMC3937915. |
| 1. **Eyal N**,\*2013. Gosseries A Obamacare and conscientious objection: some introductory thoughts. *Eth Pers*; 20(1):109–117 |
| 1. **Eyal N**, Firth P\*2012. MGH Disaster Relief Ethics Group. Repeat triage in disaster relief: questions from Haiti. *PLoS Currents Disasters*; 1–8. [10.1371%2F4fbbdec6279ec](https://dx.doi.org/10.1371%2F4fbbdec6279ec). |
| 1. Zimmerman M,\* Shakya R, Pokhrel BM, **Eyal N**, Rijal BP, Shrestha RN, Sayami A 2012. Medical students’ characteristics as predictors of career practice location: retrospective cohort study tracking graduates of Nepal’s first medical college. *BMJ*; 345:e4826. [10.1136/bmj.e4826](https://doi.org/10.1136/bmj.e4826); PMID: 22893566 PMCID: PMC3419272. |
| 1. **Eyal N** 2014. Using informed consent to save trust. *J Med Ethics*; 40:437–444. [10.1136/medethics-2012-100490](https://doi.org/10.1136/medethics-2012-100490); PMID: 25180355. |
| 1. **Eyal N\***, Bärnighausen T 2012. Precommitting to serve the underserved. *Am J Bioeth*; 12(5):23–34. [10.1080/15265161.2012.665134](https://doi.org/10.1080/15265161.2012.665134); PMID: 22548519 PMCID: PMC4300339. |
| 1. **Eyal N** 2012. Reconciling informed consent with prescription drug requirements. *J Med Ethics;*38(10):589–591. [10.1136/medethics-2012-100667](https://doi.org/10.1136/medethics-2012-100667); PMID: 22865927. |
| 1. **Eyal N** 2012.Grounding public reasons in rationality: The conditionally-compassionate medical student and other challenges. *Law & Ethics of Human Rights*; 6(1):48–68. [10.1515/1938-2545.1067](https://doi.org/10.1515/1938-2545.1067). |
| 1. **Eyal N** 2011. Why treat noncompliant patients? Beyond the decent minimum account. *J Med Phil*; 36(6):572–588. [10.1093/jmp/jhr051](https://doi.org/10.1093/jmp/jhr051); PMID: 22185704. |
| 1. **Eyal N**\*, Voorhoeve AE 2011. Inequalities in HIV care: chances versus outcomes. *Amer J of Bioeth* 2011; 11(12):42–44. [/10.1080/15265161.2011.615890](https://doi.org/10.1080/15265161.2011.615890). |
| 1. Bitton A, **Eyal N**\* 2011. Too poor to treat? The complex ethics of cost-effective tobacco control. *Pub Health Eth*; 4(2):109–120. [10.1093/phe/phr014](https://doi.org/10.1093/phe/phr014). |
| 1. **Eyal N\***,Hurst SA 2011. Scaling up changes in doctors’ education for rural retention: a comment on World Health Organization recommendations. *Bulletin of the World Health Organization*; 89(2):83. |
| 1. **Eyal N** 2010. Near-universal basic income. *Basic Income Studies*; 5(1):1–26. [10.2202/1932-0183.1149](https://doi.org/10.2202/1932-0183.1149) |
| 1. Sofaer N\*, **Eyal N** 2010.Translational research beyond approval: A two-stage ethics review. *Amer J of Bioeth*; 10: W1–3. [10.1080/15265161.2010.500199](https://doi.org/10.1080/15265161.2010.500199); PMID: 20694895. |
| 1. Sofaer N\*, **Eyal N** 2010.The diverse ethics of translational research. *Amer J of Bioeth*; 10(8), with seven responses: 19–30. [10.1080/15265161.2010.494214](https://doi.org/10.1080/15265161.2010.494214); PMID: 20694901. |
| 1. **Eyal N** 2009**.** Is the Body Special? Article-length essay–C. Fabre, Whose body is it anyway? ***Utilitas*; 21(2): 233-45.** [10.1017/S0953820809003513](https://doi.org/10.1017/S0953820809003513). 2. **Eyal N**, Hurst SA 2008. Physician brain drain–can nothing be done? *Public Health Ethics*; 1(2):180-192.  |  | | --- | | [10.1093/phe/phn026](https://doi.org/10.1093/phe/phn026). |  1. Eyal N 2008. Utilitarianism an d coercion. *Notizie di Politeia;* 24(90):108-123. |
| 1. **Eyal N** 2007.Egalitarian justice and innocent choice. *JESP*; 2(1):1–18. <https://heinonline.org/HOL/P?h=hein.journals/jetshy2&i=1>. |
| 1. **Eyal N** 2006. If you’re an egalitarian, how come you’re so *inegalitarian* about your body? *Iyyun*; 55:299–309. [www.jstor.org/stable/23354444](http://www.jstor.org/stable/23354444). |
| 1. **Eyal N** 2005. Perhaps the most important primary good: Self-respect and Rawls’s principles of justice. *Politics, Philosophy, and Economics*; 4(2):195–219. [10.1177%2F1470594X05052538](https://doi.org/10.1177%2F1470594X05052538). |

**Peer-reviewed encyclopedic entries and chapters**

|  |
| --- |
| 1. **Eyal N.** Utilitarianism and Research Ethics. In: MacAskill W, Meissner D, Chappell R, editors. *Introduction to Utilitarianism: An Online Textbook* [Utilitarianism.net]. Oxford. forthcoming. 2. **Eyal N.** Ethical Issues in Disaster Medicine. In: Ciottone GR, editor. *Disaster Medicine* (chapter 11). 2nd ed. Elsevier: Philadelphia, PA: Elsevier; 2016: 67-74. Substnatially revised 3rd edition forthcomning May 2023. 3. **Eyal N.** Informed consent. *Stanford Encyclopedia of Philosophy*. Substantially revised 2019 (originally published 2011). <http://plato.stanford.edu/entries/informed-consent/>. As of September 28, 2016, downloaded 39,574 times during the preceding full academic year |
| 1. **Eyal N** Concentrated risk, the Coventry Blitz, Chamberlain’s cancer. In: Cohen IG, N Daniels, N Eyal, eds. *Identified vs Statistical Persons*. New York: Oxford UP, 2015 <https://www.researchgate.net/deref/http%3A%2F%2Fdx.doi.org%2F10.1093%2Facprof%3Aoso%2F9780190217471.003.0007> |
| 1. Cohen\* IG, Daniels N, **Eyal N.** Introduction. In our (eds). *Identified vs statistical lives*. New York: Oxford UP; 2015 |
| 1. **Eyal N,** Hurst SA\*. Do Health Workers have a Duty to Work in Underserved Areas? In: Arras JD, Fenton E, Kukla R, eds. *The Routledge Companion to Bioethics*. New York: Routledge, 2014: 114–32. <https://archive-ouverte.unige.ch/unige:73009> 2. **Eyal N** The Regulation of risk: an introduction. In IG Cohen & H Fernandez Lynch, eds., *The Future of Human Subjects Research Regulation*. Cambridge, Mass.: MIT Press, 2014:27–29 |
| 1. **Eyal N**\*, Bärnighausen T. Conditioning medical scholarships on long, future service: a defense. I. G. Cohen, ed, *The Globalization of Health Care: Legal and Ethical Challenges.* New York: Oxford UP, 2013 |
| 1. **Eyal N** Global health impact labels. In E Emanuel, J Millum, eds, *Global Justice & Bioethics.* Oxford UP, 2012. |
| 1. Lippert-Rasmussen K\*, **Eyal N** Equality and egalitarianism. In R Chadwick, ed., *Encyclopedia of Applied Ethics*, 2nd Edition, Vol. 2. San Diego: Academic Press, 2012:141–48. [10.1016/B978-0-12-373932-2.00305-7](https://doi.org/10.1016/B978-0-12-373932-2.00305-7) |
| 1. **Eyal N** Leveling down health. In N Eyal, OF Norheim, SA Hurst, and D Wikler, eds, *Inequalities in Health: Concepts, Measures, and Ethics.* New York: Oxford UP, 2013:194–213 |
| 1. **Eyal N**, Norheim OF**\*,** Hurst SA, Marchand S, Wikler D. Inequalities and Inequities in Health. In N Eyal, O Norheim, SA Hurst, and D Wikler, eds, *Inequalities in Health: Concepts, Measures, and Ethics.* New York: Oxford UP, 2013: 1–10 |
| 1. **Eyal N** Hurst S. A. Coercion in the fight against medical brain drain. R Shah, ed, 2010. *The International Migration of Health Workers: Ethics, Rights and Justice.* London: Palgrave MacMillan, 137–158. [10.1057/9780230307292\_10](https://doi.org/10.1057/9780230307292_10) |
| 1. **Eyal N** 2007.Poverty reduction and equality with strong incentives: the brighter side of false needs. In: J Ryberg, TS Petersen & C Wolff (eds.), New Waves in Applied Ethics. London: Palgrave-MacMillan:182–216 |

**Peer-reviewed edited volumes** (the full CV lists also several edited peer-reviewed journal symposia)

|  |
| --- |
| 1. **Eyal N**, SA Hurst, CJL Murray, SA Schroeder and D Wikler, eds. (2020). *Measuring the Global Burden of Disease*. Population-Level Bioethics. New York: Oxford UP 2. Cohen IG, Daniels N, **Eyal N**, eds. 2015 *Identified vs. Statistical Persons.* New York: Oxford UP |
| 1. **Eyal N**, Norheim OF, Hurst SA, Wikler D, eds. 2013. *Inequalities in Health: Concepts, Measures, and Ethics*. Oxford UP |

**A book-length WHO report**

1. Consultative Group, incl. **Eyal N** 2014. *Making Fair Choices on the Path to Universal Health Coverage—Final Report of the WHO Consultative Group on Equity and UHC*. Geneva: WHO. French and Spanish editions: 2015. [www.who.int/publications/i/item/9789241507158](http://www.who.int/publications/i/item/9789241507158).

**Letters**

1. **Eyal N.** 2022. Longtermists should take climate change very seriously. *EA Forum*. Oct 3. <https://forum.effectivealtruism.org/posts/iWH4oxaHmfRgSSTcm/longtermists-should-take-climate-change-very-seriously>.
2. Steuwer B, Eyal N. SARS-CoV-2 Human Challenge Studies. *N Engl J Med*. 2021 Sep 29:10.1056/NEJMc2113574#sa1. [10.1056/NEJMc2113574](https://www.nejm.org/doi/10.1056/NEJMc2113574). Epub ahead of print. PMID: 34587380.
3. **Eyal N**,\* Caplan A, Plotkin S, 2021. COVID vaccine efficacy against the B.1.351 (“South African”) variant-The urgent need to lay the groundwork for possible future challenge studies. *Hum Vaccin Immunother*. Apr 27:1-2. Epub ahead of print. PMID: 33905309.
4. **Eyal N** 2020**.** Unnecessary hesitancy on human vaccine tests. *Science* 369(6500): 150-151.
5. **Eyal N**, Lipsitch M, Smith PG 2020. Response to Hasford and to Spinola et al. *J Infect Dis*.;222, (9),’1574–1575. [10.1093/infdis/jiaa458](https://doi.org/10.1093/infdis/jiaa458).
6. **Eyal N**, Lipsitch M, Smith PG. 2020. Response to Dawson et al. *J Infect Dis*. E-pub 4 June, [10.1093/infdis/jiaa315](https://doi.org/10.1093/infdis/jiaa315)
7. **Eyal N**, Lipsitch M, Smith PG. 2020 Response to Cioffi. *J Infect Dis*.; 222(1):169-170. [10.1093/infdis/jiaa217](file:///\\172.19.21.162\Users\nireyal\Documents\CV\3pp%20CV\10.1093\infdis\jiaa217)
8. Firth P, **Eyal N**. (2020) Allocating Medical Resources in the Time of Covid-19. *N Engl J Med*.; 382(22):e79. [10.1056/NEJMc2009666](doi:%20%2010.1056/NEJMc2009666,), PMID: 32343501
9. Zhang, Y\*, Bärnighausen T, **Eyal N** 2019. Reply. *JAIDS* 82(2): e41. [10.1097/QAI.0000000000002127](https://doi.org/10.1097/QAI.0000000000002127); PMID: 31513077 PMCID: PMC6749966

# INVITED LECTURES, CONFERENCE LECTURES: Full CV lists 110 international, 45 national, 15 regional, many local talks.

# TEACHING, TRAINING, AND CONSULTING (on full CV, including repeat consultations to WHO, PAHO, IPSP, IHME…)*.*

# MEDIA INTERVIEWS: A frequent commentator, who gave a *TED* talk*, Guardian, NYT, Washington Post, Bloomberg, CNN,* *CNBC*, and many other leading newspapers, TV and radio stations, and other media around the world.

# CURRENT FUNDING

2022-2023 *Longtermist biosecurity.* Longview Foundation 2039320. Role: PI, Award: $932,611.

2020-2021 *RAPID: Responsible conduct of accelerated SARS-CoV-2 vaccine research through challenge trials.* National Science Foundation 2039320. Role: PI, Award: $200,000.

|  |  |
| --- | --- |
| 2019-2020 | *Bioethical issues research supplement to Physicians' Perceptions, Attitudes, and Communication of E-cigarettes (PACE)-*3R01CA190444-05S1 from National Cancer Institute. (Role: Co-Investigator, C. Delnevo PI). Award ($89,533(D)/$142,357(T)) |
| 2017-2020 | *Health policy trials: method, voice, and ethics.* Wellcome 208766/Z/17/Z -PI (with T. Bärnighausen, M. Leshabari, M. Sarker, D. Wikler), Euro 900,000 in total. |
| 2015-2020 | *HIV cure studies: risk, risk perception, and ethics.* NIAID - 1 R01 AI114617-01A1. PI, $1,405,705 (Currently under NCE). |

# PAST FUNDING (full CV also lists past funding from *CIHR*, *Brocher*, *Safra Center*, *Harvard Global Health Institute*, and *NORAD*)

|  |  |  |
| --- | --- | --- |
| 2016-2017 | Supplement grant for the latter (NIAID 3R01AI114617-03S1). Total funding: $86,027 (Direct Costs: $70,652; Indirect Costs: $15,375). PI. For Brandon Brown. Currently awaiting NIH response on Year 2 funding. | |
| 2016-2019 | *Development Initiative for Ethical Review and Oversight of Health Research Involving Human Subjects in Rwanda.* Fogarty – 1R25 TW010298-01. PI (with Bern Friedland), $1,218,293 when the project was planned for a 2021 end-date. Budget given an updated (May 2019) end-date is still pending. | |
| 20142015 | *HIV cure studies: risk, risk perception, and ethics.* NIAID - 1 R56 AI114617-01. PI, $527,747 (R01 bridge funding). |
| 2013-2015 | *The Ethics of Electronic Adherence Monitoring for HIV Research and Care in Uganda.* NIH/NIAID - R21 AI108329-01. PI (with Jessica Haberer), $417,746. |

# HONORS & PRIZES

|  |  |
| --- | --- |
| 2018 | Lady Davis Fellowship, Hebrew University of Jerusalem. |
| 2014 | Nominated for the Donald O’Hara Faculty Prize for Excellence in Teaching, Harvard Medical School |
| 2013 | Certificate of excellence in tutoring, Harvard Med. Sch.; Rector Award**,** Roskilde U, Denmark; LS Rockefeller Fellowship, Princeton U. Ctr for Human Values (forwent to focus on work at HMS). |
| 2011 | Academics Stand Against Poverty (ASAP) Award, MacMillan Center, Yale University |
| 2010 | Mark S. Ehrenreich Prize in Healthcare Ethics Research, University of S. California and the International Association of Bioethics, for the best paper at the IAB 2010 Congress. |
| 2009 | Edmund J. Safra Fellowship in Ethics |
| 2006 | Young Scholar Award, Ethics and Public Life Program, Cornell University |
| 2003 | Nominated by Oxford University for the Barker Prize, Political Studies Association |
| 2002 | Barbinder-Watson Fund Prize, St. Hugh’s College, Oxford University |
| 2001 | Scatcherd Scholarship, Oxford University |
| 2000 | Anglo-Israel Association Prize |
| 1999 | Anglo-Jewish Association Prize; Karten Prize, Ian-Karten Trust; AVI Prize, AVI Institute; Larkinson Scholarship in Politics, St. Hugh’s College, Oxford U.; Wingate Harold Hyam Foundation Award. |
| 1998 | Lavon Prize for research on labor issues, Lavon Institute for Labour Movement Research, Israel; HaEzrahi Prize for outstanding MA student, Hebrew U. Dept. of Philosophy |
| 1994 | Outstanding BA student award, Tel Aviv U. Department of History |

# A SELECTION OF CONFERENCES ORGANIZED (The full CV states many others)

|  |  |
| --- | --- |
| 2018 | Co-organizer: Ordeals for health: Ethics and efficient delivery (Safra Center, HSPH, HMS, HLS, HKS, Wellcome) |
| 2017 | Co-organizer: Efficacy testing of vaccines for infectious disease outbreaks funding (Ethox) |
| 2017 | Organizer: Risk to nonparticipants in medical research: the ethics (NIAID) |
| 2010,2,4,6,8 | Co-organizer: five summer schools: Brocher Summer Academy in Population-Level Bioethics. |
| 2012-2013 | Co-organizer: Three workshops for the WHO workgroup on *Equity Considerations in the WHO Action Plan on Financing Universal Coverage* – in Norway, Switzerland, and the US (NORAD, IDRC, Swiss NSF, Brocher) |
| 2012 | Co-organizer, *Egalitarianisms: Current Debates* *on Equality/Priority in Health, Wealth, Welfare*(McGill, CIHR) |
| 2009-2012 | Co-organizer: Harvard University Program in Ethics and Health annual and other conferences. |

# MAIN COMMITTEE SERVICE POSITIONS (the full CV lists many others)

2021-pres. Chair, Search Committee for CPLB faculty, Rutgers U.

2021-pres. Member, Search Committees for GHI faculty and for IFH Director, Rutgers U.

2020-pres. Member, Association of Bioethics Program Directors

2020-pres. Advisory Board Member, 1 Day Sooner

2020-pres. Member, NJ Department of Health Professional Advisory Committee (PAC)

2020-pres. Member, Coronavirus Vaccine Human Challenge Working Group, Rutgers U.

2020-pres Member, COVID-19 Testing Protocol Action Group (TPAG), Rutgers U.

2020-pres. Member, Rutgers University Medical Cannabis Workgroup, Rutgers U.

2020-pres. Member, Wellcome Trust advisory committee on human challenge trials for Coronavirus

2020-pres. Member, RWJ-Barnabas Taskforce on health system response to Crisis Standards of Care during the COVID-19 crisis.

2019-pres. Member, Rutgers University Microbial Protection (RUMP) advisory board.

2015-2017 Member, Harvard TH Chan faculty advisory group that designed, runs the pilot for, a new MPH integrated core course.

2014-pres. Chair, Subcommittee for Revising the Massachusetts draft guidelines on Emergency Preparedness,

Task Force on Ethical Aspects of Emergency Preparedness

2014-2016 Member, International AIDS Society task force, “Towards an HIV cure”

2013-2016 Chair, American Philosophical Association Committee on Philosophy and Medicine

2013-2017 Chair, American Society for Bioethics & the Humanities *Philosophy* (since 2015: + *History*) Subcommittee

2011-2019 Member, University Faculty Committee, EJ Safra Center for Ethics, Harvard University

# EDITORIAL (the full CV lists additional editorial roles and ad-hoc refereeing for 54 journals).

2018-pres. International Editorial Board member, *Behavioral Applied Ethics* (Rowman and Littlefield)

2015-pres. Board of Advisors member, *Oxford Studies in Political Philosophy.*

2015-pres. Editorial Board member, *Public Health ethics.*

2014-2021 Advisory board member, *Social Theory and Practice.*

2013-pres. Editorial board member, *Applied Ethics* (Oxford UP)*.*

2013-pres. Editorial board member, *I**nternational J of Health Policy & Management.*

2011-pres. Series co-editor, *Population-Level Bioethics*, Oxford UP, New York.

2010-pres. Associate editor and book review editor (Bioethics), *Ethical Perspectives.*